Catalyst Pharmaceuticals (NASDAQ:CPRX) Upgraded by StockNews.com to Strong-Buy Rating

Catalyst Pharmaceuticals (NASDAQ:CPRX) was upgraded by StockNews.com from a “buy” rating to a “strong-buy” rating in a report released on Friday.

Several other research firms also recently issued reports on CPRX. Stephens began coverage on Catalyst Pharmaceuticals in a research note on Monday, November 18th. They issued an “overweight” rating and a $35.00 price objective for the company. Truist Financial upped their price target on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a “buy” rating in a research report on Monday, November 11th. Finally, HC Wainwright reiterated a “buy” rating and set a $30.00 price target on shares of Catalyst Pharmaceuticals in a report on Friday, November 8th. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $31.14.

Catalyst Pharmaceuticals Stock Down 1.0 %

Shares of CPRX opened at $21.31 on Friday. The stock has a market cap of $2.54 billion, a PE ratio of 18.06, a PEG ratio of 3.35 and a beta of 0.79. Catalyst Pharmaceuticals has a 12-month low of $13.12 and a 12-month high of $24.27. The business has a 50-day simple moving average of $21.80 and a two-hundred day simple moving average of $19.77.

Insider Buying and Selling at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, Director Molly Harper sold 17,500 shares of the firm’s stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $22.00, for a total transaction of $385,000.00. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Steve Miller sold 50,000 shares of Catalyst Pharmaceuticals stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $21.93, for a total value of $1,096,500.00. Following the sale, the insider now directly owns 686,996 shares of the company’s stock, valued at approximately $15,065,822.28. This trade represents a 6.78 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 79,500 shares of company stock valued at $1,754,140 in the last three months. Company insiders own 11.00% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Dimensional Fund Advisors LP lifted its holdings in shares of Catalyst Pharmaceuticals by 9.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 3,000,756 shares of the biopharmaceutical company’s stock worth $46,479,000 after acquiring an additional 263,099 shares during the last quarter. Pacer Advisors Inc. lifted its stake in Catalyst Pharmaceuticals by 130,918.8% in the second quarter. Pacer Advisors Inc. now owns 2,967,575 shares of the biopharmaceutical company’s stock worth $45,968,000 after purchasing an additional 2,965,310 shares during the last quarter. Renaissance Technologies LLC boosted its position in Catalyst Pharmaceuticals by 15.2% during the second quarter. Renaissance Technologies LLC now owns 2,175,727 shares of the biopharmaceutical company’s stock valued at $33,702,000 after buying an additional 287,300 shares during the period. Charles Schwab Investment Management Inc. grew its stake in shares of Catalyst Pharmaceuticals by 4.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,167,743 shares of the biopharmaceutical company’s stock valued at $23,215,000 after buying an additional 50,804 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its holdings in shares of Catalyst Pharmaceuticals by 2.1% in the second quarter. Bank of New York Mellon Corp now owns 834,415 shares of the biopharmaceutical company’s stock worth $12,925,000 after buying an additional 16,960 shares during the period. 79.22% of the stock is currently owned by institutional investors.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.